Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 2/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2725463 | 0.85 | PDE4A (0.37) | CYP3A4PDE4ACYP17A1CYP2C9CYP2C19 | |
| SCHEMBL2723714 | 0.83 | CYP3A4 (0.40) | CYP3A4 | |
| SCHEMBL2723287 | 0.81 | CYP3A4 (0.38) | CYP3A4PDE4ACYP17A1 | |
| SCHEMBL2723597 | 0.77 | CYP3A4 (0.50) | CYP3A4CYP17A1CYP2C9CYP2C19SCN9A | |
| SCHEMBL2724416 | 0.77 | CYP3A4 (0.36) | CYP3A4CYP17A1 | |
| SCHEMBL2723719 | 0.75 | CYP3A4 (0.50) | CYP3A4CYP17A1CYP2C9SCN9A | |
| SCHEMBL15294420 | 0.69 | CYP3A4 (0.50) | CYP3A4 | |
| SCHEMBL5020174 | 0.68 | CYP17A1 (0.36) | CYP3A4PDE4ACYP17A1CYP2C9CYP2C19 | |
| SCHEMBL2723699 | 0.68 | CYP3A4 (0.48) | CYP3A4 | |
| SCHEMBL4562418 | 0.67 | NT5E (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056855-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2015-06-16 | — | — | US | claimed |
| EP-2632903-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2013-09-04 | — | — | EP | claimed |
| WO-2012058529-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | WO | claimed |
| US-9056855-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056855-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056855-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20130261135-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261135-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261135-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2632903-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012058529-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012058529-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261135-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CYP3A4 558/4885PDE4A 1932/4885CYP17A1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.